SRR25043623
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.560
- INTERFERON_ALPHA_RESPONSE+0.440
- OXIDATIVE_PHOSPHORYLATION+0.420
- FATTY_ACID_METABOLISM+0.310
- ADIPOGENESIS+0.290
- INTERFERON_GAMMA_RESPONSE+0.280
- ALLOGRAFT_REJECTION+0.220
- KRAS_SIGNALING_UP+0.180
- BILE_ACID_METABOLISM+0.140
- KRAS_SIGNALING_DN+0.130
Top 10 suppressed
- MYC_TARGETS_V2-0.520
- E2F_TARGETS-0.420
- CHOLESTEROL_HOMEOSTASIS-0.410
- TNFA_SIGNALING_VIA_NFKB-0.410
- UNFOLDED_PROTEIN_RESPONSE-0.400
- DNA_REPAIR-0.380
- G2M_CHECKPOINT-0.380
- MYC_TARGETS_V1-0.360
- MTORC1_SIGNALING-0.340
- P53_PATHWAY-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2278856 | — | — | 0.848 |
| 2 | SRR612623 | GTEX | — | 0.800 |
| 3 | SRR613438 | GTEX | — | 0.795 |
| 4 | SRR614563 | GTEX | — | 0.787 |
| 5 | SRR612380 | GTEX | — | 0.779 |
| 6 | SRR612899 | GTEX | — | 0.766 |
| 7 | ERR2278882 | — | — | 0.747 |
| 8 | ERR2278854 | — | — | 0.734 |
| 9 | ERR2598293 | fetal | fetal | 0.730 |
| 10 | C3N-00223 | — | cohortA1 | 0.727 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.560 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.290 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.040 | Inavolisib | — uncovered |
| COMPLEMENT | 0.030 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.020 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |